

## Repression of the *pyr* Operon in *Lactobacillus plantarum* Prevents Its Ability To Grow at Low Carbon Dioxide Levels

Hervé Nicoloff,<sup>1†</sup> Aram Elagöz,<sup>1‡</sup> Florence Arsène-Plöetze,<sup>1</sup> Benoît Kammerer,<sup>1</sup> Jan Martinussen,<sup>2</sup> and Françoise Bringel<sup>1\*</sup>

Laboratoire de Dynamique, Evolution et Expression de Génomes de Microorganismes, Université Louis Pasteur/CNRS FRE 2326, Strasbourg, France,<sup>1</sup> and Biocentrum, Technical University of Denmark, Lyngby, Denmark<sup>2</sup>

Received 19 July 2004/Accepted 12 December 2004

Carbamoyl phosphate is a precursor for both arginine and pyrimidine biosynthesis. In *Lactobacillus plantarum*, carbamoyl phosphate is synthesized from glutamine, ATP, and carbon dioxide by two sets of identified genes encoding carbamoyl phosphate synthase (CPS). The expression of the *carAB* operon (encoding CPS-A) responds to arginine availability, whereas *pyrAaAb* (encoding CPS-P) is part of the *pyrRIBCaaAbDFE* operon coding for the de novo pyrimidine pathway repressed by exogenous uracil. The *pyr* operon is regulated by transcription attenuation mediated by a *trans*-acting repressor that binds to the *pyr* mRNA attenuation site in response to intracellular UMP/phosphoribosyl pyrophosphate pools. Intracellular pyrimidine triphosphate nucleoside pools were lower in mutant FB335 (*carAB* deletion) harboring only CPS-P than in the wild-type strain harboring both CPS-A and CPS-P. Thus, CPS-P activity is the limiting step in pyrimidine synthesis. FB335 is unable to grow in the presence of uracil due to a lack of sufficient carbamoyl phosphate required for arginine biosynthesis. Forty independent spontaneous FB335-derived mutants that have lost regulation of the *pyr* operon were readily obtained by their ability to grow in the presence of uracil and absence of arginine; 26 harbored mutations in the *pyrRI-pyrB* loci. One was a prototroph with a deletion of both *pyrRI* and the transcription attenuation site that resulted in large amounts of excreted pyrimidine nucleotides and increased intracellular UTP and CTP pools compared to wild-type levels. Low pyrimidine-independent expression of the *pyr* operon was obtained by antiterminator site-directed mutagenesis. The resulting AE1023 strain had reduced UTP and CTP pools and had the phenotype of a high-CO<sub>2</sub>-requiring auxotroph, since it was able to synthesize sufficient arginine and pyrimidines only in CO<sub>2</sub>-enriched air. Therefore, growth inhibition without CO<sub>2</sub> enrichment may be due to low carbamoyl phosphate pools from lack of CPS activity.

In all organisms, pyrimidine nucleotides may be synthesized either de novo from bicarbonate and intermediates of central metabolism or via salvage of preformed pyrimidine bases and nucleosides present in the surrounding medium (17). When no exogenous pyrimidines are present in the culture, most organisms can perform de novo pyrimidine synthesis and produce UMP (Fig. 1). Bacteria living on rich medium that provide nucleotide precursors may lose their ability to synthesize them. Lactic acid bacteria are fastidious, and at least one third of natural isolates of *Lactobacillus plantarum* are high-CO<sub>2</sub>-requiring auxotrophs for pyrimidine nucleotides and arginine (5).

Carbon dioxide hydrates into bicarbonate, which is a substrate for carbamoyl phosphate synthesis catalyzed by the carbamoyl phosphate synthase (CPS). Carbamoyl phosphate is a precursor of both pyrimidine nucleotide and arginine synthesis. In *L. plantarum*, carbamoyl phosphate is synthesized by two CPSs, CPS-P and CPS-A, encoded by *pyrAaAb* and *carAB*,

respectively. The expression of *pyrAaAb* and *carAB* is subject to transcriptional regulation. Whereas *pyrAaAb* is repressed by pyrimidines, *carAB* responds to the arginine level. Carbamoyl phosphate is produced mainly from the pyrimidine-regulated CPS-P and not from the arginine-regulated CPS-A in wild-type *L. plantarum* when cultivated in ordinary air (without CO<sub>2</sub> enrichment) as demonstrated with *pyrAaAb* and *carAB* mutants (19). High-CO<sub>2</sub>-requiring auxotrophs may have limited carbamoyl phosphate availability resulting from altered or deregulated pyrimidine-related genes (5). As a first step to identifying the genetic lesions or regulation alterations that occur in natural high-CO<sub>2</sub>-requiring auxotrophs, the pyrimidine-dependent regulation of nucleotide pools in *L. plantarum* was investigated in this work.

In *L. plantarum*, the enzymes catalyzing the de novo pyrimidine pathway are encoded by the *pyr* operon (3, 15, 19). The first gene of the operon is *pyrRI*, a *Bacillus subtilis pyrR*-like gene (Fig. 2A). In *B. subtilis*, PyrR regulates the expression of the downstream genes of the *pyr* operon by modulating the attenuation of transcription at three points in response to exogenous pyrimidines (11, 24). In the presence of UMP, PyrR binds to the target RNA that folds into a stem-loop structure called the anti-antiterminator, allowing the formation of the downstream termination structure, resulting in transcription termination. The phosphoribosyl pyrophosphate (PRPP) antagonizes the action of UMP on termination. PyrR also has catalytic activity as a uracil phosphoribosyltransferase, although this activity has no physiological importance (12). Con-

\* Corresponding author. Mailing address: Laboratoire de Dynamique, Evolution et Expression de Génomes de Microorganismes, Université Louis Pasteur/CNRS FRE 2326, 28 rue Goethe, F-67083 Strasbourg, France. Phone: 33 3 90 24 18 15. Fax: 33 3 90 24 20 28. E-mail: bringel@gem.u-strasbg.fr.

† Present address: Center For Adaptation Genetics and Drug Resistance, Departments of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Mass.

‡ Present address: AstraZeneca R&D Montreal, Saint-Laurent, Montreal, Quebec, Canada.




FIG. 1. Simplified pyrimidine biosynthesis and link with arginine biosynthesis in an *L. plantarum*  $\Delta carAB$  mutant. Carbamoyl phosphate (CP) is a common precursor in arginine and pyrimidine biosynthesis. The wild-type strain CCM 1904 has two functional carbamoyl phosphate synthases (CPSs) (19). The *carAB* operon codes for the two subunits of the arginine-repressed CPS, CPS-A. The *pyrAaAb* genes present on the *pyr* operon (6) code for the pyrimidine-regulated CPS, CPS-P (19). Exogenous uracil enters the cell and is metabolized to UMP, which negatively controls the *pyr* operon, including the *pyrAaAb* genes. The *carAB* genes have been deleted in strain FB335, so that CPS-P is the only source of carbamoyl phosphate for pyrimidine and arginine biosynthesis (19). In the presence of added uracil, FB335 is unable to grow for lack of carbamoyl phosphate for arginine synthesis. For this reason, FB335 is sensitive to uracil (Ura<sup>s</sup>).

sequently, the coregulators PRPP and UMP are proposed to bind to the active site of PyrR, like the substrate and product molecules. When the UMP/PRPP ratio is low, PyrR does not bind its RNA target so that the antitermination loop is formed and transcription proceeds beyond the terminator.

In vitro analysis of the three known *B. subtilis* *pyr* attenuation sites suggests that the RNA polymerase pauses after synthesis of the leading anti-antiterminator sequence so that the more stable antiterminator loop cannot be formed, allowing PyrR to bind to the anti-antiterminator loop (25). *B. subtilis* PyrR acts probably as a dimer (2), and the crystal structure of the ligand-free dimeric form has recently been resolved (accession no. 1A4X). Several regions involved in mRNA binding (8, 20), coregulator binding, and the dimerization process were characterized, and the structure of the domain homologous to other phosphoribosyltransferases was studied (23). A second *pyrR*-like gene was found in *L. plantarum* upstream of *pyrAa2* and *pyrAb2* (Fig. 2B). The resulting CPS is predicted to be nonfunctional, since frameshift mutations are found in the pseudogene *pyrAb2* (10).

Pyrimidine-regulated transcription attenuation may be common in bacteria, as previously suggested (22). Sequence analysis of the *L. plantarum* *pyr* operon 5' leader region suggested that in this organism the *pyr* operon may be regulated by transcription attenuation at two possible attenuation sites (Fig. 2A). The first attenuation site is located between the promoter and *pyrR1*. The second attenuator is located between *pyrR1* and *pyrB* (6). In this work, the occurrence of pyrimidine-dependent transcription attenuation of the *pyr* operon was as-

sessed on RNA extracted from *L. plantarum* grown in the presence and absence of exogenous uracil. Moreover, use of a classical genetic screening for deregulated mutants, analysis of independent mutants allowed us to study in vivo pyrimidine regulation of the *pyr* operon in *L. plantarum*. The *pyr* operon expression is modulated by PyrR1 and the sequence of the attenuation site located between *pyrR1* and *pyrB*. The inability of some deregulated mutants to grow in air without additional carbon dioxide was linked to reduced nucleotide pool sizes.

#### MATERIALS AND METHODS

***L. plantarum* strains and growth conditions.** All strains derive from the pyrimidine prototrophic strain CCM 1904, as documented in Table 1. Routine *Lactobacillus* propagation was done in MRS (Difco Laboratories) at 30°C without agitation. The defined *Lactobacillus* medium DLA (4) was used when the concentration of pyrimidines needed to be controlled. When required, uracil was added at 50  $\mu$ g/ml. For nucleotide pool determination, DLP medium was used. Compared to DLA, the DLP medium has less phosphates (2 mM instead of 10 mM), no cystine, and Tween 80 (1 g) replaced oleic acid and Tween 40.

**Physiological tests.** Nutritional requirements were tested at 30°C on DLA agar plates supplemented or not with 50  $\mu$ g of uracil (DLAU) or arginine (DLAA) per ml, in aerobiosis or CO<sub>2</sub>-enriched air. Aerobiosis was obtained by incubation in ordinary air. To calibrate the air at 4% pCO<sub>2</sub>, a water-jacketed CH/P incubator (Forma Scientific) was used. To test whether the different mutants excreted pyrimidines, the amount of pyrimidines present in the culture supernatant was measured with a bioassay. The indicator strain HN217 is a stable *L. plantarum* Ura<sup>-</sup> Arg<sup>-</sup> mutant because of the *pyrAaAb carAB* gene deletions (19). HN217 only grows in DLAA when pyrimidines are supplied.

Strains to be tested were cultivated without agitation for 3 days at 30°C in 2 ml of DLAA broth. Cells were eliminated by centrifugation (3,000  $\times$  g for 6 min). The supernatant was filter sterilized with a 0.45- $\mu$ m-pore-size Millipore filter and mixed to new DLAA broth before inoculation with the indicator strain. To




FIG. 2. Gene organization of the *pyr* genes. A, Scheme of the transcription attenuation mechanism of the biosynthetic pyrimidine operon *pyrR1BCAaAbDFE* (EMBL database accession no. Z54240). Two transcription attenuators are found in the 5' leader sequence of the *pyr* operon (6) which consists of overlapping repeated sequences that form exclusive RNA loops such as the anti-antiterminator loop (aat), the antiterminator loop (at), and terminator loop (t). Terminators t1, t2, and t3 are indicated. B, *pyrR2pyrAa2Ab2* cluster (EMBL database accession no. AJ617795) with the pseudogene *pyrAb2*.

correlate the indicator strain growth yield with uracil concentrations and to compare the mutants with the parental FB335 strain, some used DLAA medium (after growth of FB335) was mixed with some fresh medium supplied with increasing amounts of uracil and inoculated with the indicator strain. After 4 days of incubation at 30°C without agitation, the growth yield was established by measuring the optical density at 660 nm. The cell densities in the culture with known amounts of uracil (0 to 7.5 µg/ml) were used to quantify the uracil excretion of the different mutants.

**Nucleic acid techniques.** Three genetic loci were PCR amplified with the primer sets described in Table 2. Overlapping PCR products were amplified when the genetic loci exceeded 3 kb such as for *pyrAaAb* and the *pyrR2* loci. PCR amplifications were done on a Peltier thermal cycler PTC-200 (MJ Research) with *Taq* polymerase (Sigma). PCR amplifications started with denaturation at 95°C for 1 min. Then, 35 cycles of successive denaturation (20 s at 94°C), hybridization (20 s at 56°C), and elongation (5 min at 72°C) were performed. The PCR was completed by a 10-min postelongation treatment at 72°C. Prior to sequencing of the PCR products, the nonincorporated primers and deoxynucleoside triphosphates were eliminated by passage on a Microspin S-400 HR column

(Pharmacia Biotech). RNA extraction, primer extension, and Northern hybridization were performed according to Nicoloff et al. (19).

**Spontaneous mutant selection and site-specific mutagenesis.** Independent spontaneous uracil-resistant (*Ura*<sup>r</sup>) mutants of strain FB335 were selected on DLAA plates incubated 4 days at 30°C in 4% CO<sub>2</sub>-enriched air as previously described (18). Mutagenesis by allelic replacement has been successfully used in *L. plantarum* CCM 1904 with pGID23-derived plasmids (19). Such plasmids were constructed to mutate antiterminator site 2 (at2) in AE1023 with plasmid pAE1017, anti-antiterminator site 2 (aat2) in AE1021 with plasmid pAE1015, and *pyrR1* in AE1026 with plasmid pAE1020.

To construct plasmid pAE1017, the PCR products of two amplifications with *L. plantarum* CCM 1904 genomic DNA as the template and primer set aem5 and 2056 and primer set aem6 and N46 were merged by a second PCR with primers N46 and 2056. Primers aem5 (55-mers) and aem6 (54-mers) have an overlapping 40-nucleotide-long sequence and 12 different nucleotides compared to the wild-type at2 sequence (Table 2). The resulting 1,340-bp PCR product was BclI restricted and cloned into the linearized BamHI pGID23 vector. To construct pAE1015, the PCR products of two amplifications with primer set aem1 and 2056

TABLE 1. Characteristics of the strains studied<sup>a</sup>

Strain	Relevant genotype	Mutant name(s)	Growth	Pyrimidine excretion (µg/ml)	Comments or reference
Wild-type CCM 1904			Prototroph	0	
CCM 1904 mutants	<i>ΔpyrD</i>	PH1021	Ura <sup>-</sup>	Not tested	9
	<i>aat2</i> (G1356A)	AE1021	Prototroph	5.7	<i>aat2</i> hexaloop mutated
	<i>at2<sup>b</sup></i>	AE1023	HCR	0	Unstable RNA <i>at2</i> loop
	<i>pyrR1</i> (G1090T)	AE1026	Prototroph	4.3	PyrR1 D104Y
	<i>ΔcarAB</i>	FB335	Ura <sup>s</sup>	0	19
			prototroph		
Pyrimidine-deregulated isolates of FB335 <sup>c</sup>					
RNA loops	<i>ΔcarAB aat2</i> (Δ1332–1349)	U1, U8, U28	Prototroph	7.3	<i>aat2</i> loop absent
	<i>ΔcarAB aat2</i> (G1358A)	U4	HCR	2.5	<i>aat2</i> hexaloop mutated
	<i>ΔcarAB aat2-at2</i> (G1360A)	U23	Prototroph	6.7	<i>aat2</i> loop mutated
	<i>ΔcarAB ΔpyrR1 aat2</i> (Δ886–1340)	U25	Prototroph	14.7	G36 to E180 PyrR1 deletion and <i>aat2</i> loss
	<i>ΔcarAB aat2</i> (G1361T)	U26	Prototroph	3.1	<i>aat2</i> loop mutated
	<i>ΔcarAB at2</i> (T1401G)	U33	HCR	0	<i>at2</i> loop mutated
PyrR1	<i>ΔcarAB pyrR1</i> (C1204T)	U3	Prototroph	4.6	PyrR1 P124S
	<i>ΔcarAB pyrR1</i> (G901A)	U5	Prototroph	4.0	PyrR1 G41R
	<i>ΔcarAB pyrR1</i> (G1140)	U6	Prototroph	0.4	PyrR1 M120I
	<i>ΔcarAB pyrR1</i> (C991T)	U9	Prototroph	1.8	PyrR1 R71W
	<i>ΔcarAB ΔpyrR1</i> (1228–1296)	U12	Prototroph	4.6	H170-G172 PyrR1 deletion
	<i>ΔcarAB pyrR1</i> (A1193G)	U13	Prototroph	2.3	PyrR1 H138R
	<i>ΔcarAB pyrR1</i> (G1282T)	U15	Prototroph	2.4	PyrR1 D168N
	<i>ΔcarAB pyrR1</i> (C1195T)	U16	Prototroph	1.9	PyrR1 R139C
	<i>ΔcarAB ΔpyrR1</i> (769–1041)	U17	Prototroph	8.5	No PyrR1 translated
	<i>ΔcarAB pyrR1</i> (1141 insG)	U18	Prototroph	8.6	D121-E180 PyrR1 deletion
	<i>ΔcarAB pyrR1</i> (911insT)	U19	Prototroph	7.6	F44-E180 PyrR1 deletion
	<i>ΔcarAB pyrR1</i> (G997A)	U22, U29	Prototroph	1.2	PyrR1 D73N
	<i>ΔcarAB pyrR1</i> (924insA)	U24	Prototroph	7.7	A49-E180 PyrR1 deletion
	<i>ΔcarAB ΔpyrR1</i> (795–950)	U31	HCR	6.2	V6-G57 PyrR1 deletion
	<i>ΔcarAB pyrR1</i> (ins801) <sup>d</sup>	U32	Prototroph	7.6	Q17-E180 PyrR1 deletion
	<i>ΔcarAB pyrR1</i> (G783A)	U40	HCR	7.2	PyrR1 truncated due to a point mutation in the initiation codon
	<i>ΔcarAB pyrR1</i> (C1117T)	U41	Prototroph	5.4	PyrR1 R113W

<sup>a</sup> Sequence data refer to EMBL accession number Z54240. Prototrophs grew without arginine and uracil in defined medium DLA. The growth of uracil-sensitive (Ura<sup>s</sup>) prototrophs was inhibited by uracil in the absence of arginine. The high-carbon-dioxide-requiring (HCR) auxotrophs require exogenous arginine and uracil at low carbon dioxide levels (see Table 3).

<sup>b</sup> TgTgaggaaacTTaacggAtACCAAGT; mutated bases in uppercase (nucleotides 1355 to 1379 in database accession no. Z54240).

<sup>c</sup> Uracil-resistant (Ura<sup>r</sup>) derivatives of strain FB335 that acquired the ability to grow in the presence of uracil when arginine was omitted from DLA plates incubated in CO<sub>2</sub>-enriched air.

<sup>d</sup> The inserted sequence is 5'-GCAATGACCATGCGCCGCGCTGAC-3'.

and primer set *aem2* and N46 were merged by a second PCR with primers 2072 and 2042. Primers *aem1* and *aem2* overlapped and harbored a single nucleotide mutation compared to the wild-type *aat2* (Table 2). The resulting 1,100-bp PCR product was BclI restricted and cloned into the linearized BamHI pGID023 vector. To construct pAE1020, the PCR products of two amplifications with primer sets N44 and *aem11* and N29 and *aem10* were merged by a second PCR with primers N44 and N29. Primers *aem10* and *aem11* are overlapping and harbor a single nucleotide mutation compared to the wild-type *pyrR1* coding sequence (Table 2). The 893-bp PCR product was digested with the restriction enzymes Cac8I and RsaI and cloned into the linearized SmaI vector. Selection of recombinants harboring the mutated alleles was performed as previously described (19), and the mutations were confirmed by direct sequencing on the chromosome (6).

**Intracellular nucleotide pool quantification.** The intracellular nucleoside triphosphate pool measurement in *L. plantarum* was optimized from the method described for *Lactococcus lactis* (14). Cells were grown exponentially for at least two generations in DLP medium in the presence of <sup>33</sup>P<sub>i</sub> until an optical density at 660 nm of 0.8 was reached. The <sup>33</sup>P-labeled nucleotides were extracted from *L. plantarum* by transferring 190 µl of cell culture to 20 µl of 10 M formic acid at room temperature. After three freeze-thaw cycles followed by 30 min of incubation in an ice-water bath, the cell debris were removed by centrifugation.

For analysis, 20 µl of extract was mixed with 2 µl of marker solution (nucleoside triphosphates, 5 mM each) and applied to polyethyleneimine-cellulose plates. The plates were dried under cold air, washed for 10 min in ethanol, and dried. The first dimension of chromatography was performed at room temperature in a 0.85 M KH<sub>2</sub>PO<sub>4</sub> solution adjusted to pH 3.42 by addition of an equimolar H<sub>3</sub>PO<sub>4</sub> solution. Following chromatography, the plates were washed in 10% citrate (wt/vol) and two times in distilled water. The plates were dried and chromatographed in the second dimension with 0.75 M LiCl supplemented with 7.5% H<sub>3</sub>BO<sub>3</sub> as the running buffer. The pH was adjusted to 6.8 by addition of solid LiOH. Individual nucleoside triphosphates were identified according to the spots of the unlabeled nucleoside triphosphate marker solutions visible in UV light. Finally, the plates were evaluated and enumerated in an Instant Imager. With the specific activity measured in the assays, the concentration of the individual nucleotides was then determined as a function of the radioactivity in their individual spots. In order to report nucleoside triphosphate pools as nanomoles per milligram of dry weight, we used the correlation factor 0.2 mg [dry weight] ml<sup>-1</sup> corresponded to an optical density at 450 nm equal to 1. Two independent biological replicates were performed for each condition tested.

**Nucleotide sequence accession number.** The nucleotide sequence of the *pyrR2-pyrAa2-Ab2* locus in *L. plantarum* CCM 1904 reported in this paper has been submitted to the EMBL database and assigned accession number AJ617795.



TABLE 2. Primer list

Genetic locus	PCR product		Primer name and sequence (5'→3') <sup>a</sup>	EMBL accession no.
	Use	Size (kb)		
<i>pyrR1</i> and attenuators	Amplification and sequencing	1.2	N40, GTACTAATATTAGGCGACCG (F) N29, TGTGTGCGGGTGCTATTCTC (R)	Z54240
		<i>pyrR1</i> mutagenesis	1.1	
	aat2 mutagenesis		0.5	
		0.7	aem1, TTGTTTCCAAGAGGAACG (F) 2056, CCATCGTCTGATATTCGCCG (R)	
		0.7	aem2, CGTTCCTCTTTGGAAACAA (R) N46, CCCCGTGGATTAAGGTGA (F)	
		1.1	2072, CTGACAACTAATGGCAG (F) 2042, TGTGACGGATGTTGCCAC (R)	
		at2 mutagenesis	0.7	
	0.7		aem6, <u>CGCAACTGGT ATCCGTTAA GTTCCTCACAGG</u> <u>AAAGAATTAAATGGTTTTATTCAA</u> (R) N46, see above	
	Primer extension <i>pyrR1</i> probe		0.5	
		<i>pyrB</i> probe	1.3	
	<i>pyrAaAb</i>		2.5	
2.6		2380, CGGCCAGCACATTGTCA (F) 2002, CTCAAAGCGACTGGTTACC (R)		
<i>pyrR2</i>	1.9	lp1782F, CGACAACCTTGGCTAAGCTTG (F) lp1783r, CTCGGCCAATGTCATTATGC (R)	AL935263	
	3.0	lp1783f3, CAGATGGCGCTCCTGGTCCGAC (F) l904lp1784r2, TGATACTAGTACTATCAGTG (R)	AJ617795	

<sup>a</sup> F, forward primer; R, reverse primer. Nucleotides in bold differ from the wild-type sequence, and complementary sequences between aem5 and aem6 are underlined. Primers aem11 and aem10 as well as aem1 and aem2 are complementary over their whole sequence.

## RESULTS

***L. plantarum pyr* operon is regulated by transcription attenuation.** Two putative attenuation sites followed by terminators t1 and t2, respectively, were found in the *pyr* operon 5' leader sequence (Fig. 2A). These proposed RNA hairpin structures suggested that the *pyr* operon is regulated by transcription attenuation (6). In this case, transcription initiation of the *pyr* operon is predicted to occur whether or not uracil is added to the medium. To test this, the *pyr* operon transcription start site was determined by primer extension with avian myeloblastosis virus reverse transcriptase. With primer 2071, located 11 nucleotides upstream of the *pyrR1* gene, the transcription start site was determined at nucleotide C (position 631 of EMBL sequence accession no. Z54240), which is positioned 149 nucleotides before the *pyrR1* initiation codon. A putative -10 box (TACACT) was found 6 nucleotides upstream of the transcription start site. This start site was detected with RNA extracted from cells cultivated in the absence and presence of uracil (Fig. 3A).

Once transcription is started, RNA polymerase may stop elongation at the putative t1 terminator located before *pyrR1*, at terminator t2 located in the intergenic *pyrR1-pyrB* region, and at terminator t3 located at the end of the *pyr* operon, leading to mRNAs with predicted sizes of 0.1, 0.8, and 9.7 kb, respectively. To test this model, the sizes of the *pyr* operon

mRNAs were characterized by Northern hybridization with two different probes. These probes had no sequence similarities with the smaller 0.1-kb transcript so that the activity of terminator t1 was not assessed. With a *pyrR1*-specific probe, two mRNA bands of 0.8 kb and 9.7 kb were identified. With the *pyrB*-specific probe, only the pyrimidine-repressed 9.7-kb mRNA was detected (Fig. 3B; the band around 2.5 kb obtained with the *pyrR1* and *pyrB* probes may correspond to a degradation product of the larger 9.7-kb transcript). These data show that *pyr* operon transcription initiation occurs in the presence and absence of uracil, that the *pyrR1BCAaAbDFE* transcript (9.7 kb) is detected only in cells grown without uracil, and that the *pyrR1* transcript (0.8 kb) is detected in the presence and absence of uracil. These in vivo data demonstrate that the *pyr* operon in *L. plantarum* is pyrimidine-dependently regulated by transcription attenuation with termination between the *pyrR1* and *pyrB* genes, possibly at the terminator t2 hairpin (Fig. 4A).

**Positive screening test for spontaneous mutants.** The positive screening for pyrimidine-deregulated mutants was based on the ability to supply the arginine biosynthesis pathway with sufficient carbamoyl phosphate produced by the pyrimidine-regulated CPS-P. Strain FB335 carries a deletion of the *carAB* genes, encoding the arginine-regulated CPS-A. Consequently, CPS-P is responsible for carbamoyl phosphate production for both arginine and pyrimidine biosynthesis. The presence of




FIG. 3. Pyrimidine-regulated transcription of the *L. plantarum pyr* operon. RNA was extracted from cells cultivated without agitation in defined medium without (-U) and with added uracil at a concentration of 200  $\mu\text{g/ml}$  (+U). A, Primer extension by reverse transcription with primer 2071. The same primer was used for the sequencing reaction (A, C, G, and T tracks). The transcription start site is indicated (+1). B, Northern hybridization on 13  $\mu\text{g}$  of RNA probed with two DNA fragments hybridizing to *pyrR1* and to *pyrB*. The sizes of the bands detected were deduced from molecular size markers (lane M), and relevant bands are marked: a, 0.8 kb; b, 9.7 kb.

uracil (DLAU medium) represses transcription of the *pyr* operon, which harbors the structural genes for CPS-P, so that only a limited amount of CPS-P is present. The amount of carbamoyl phosphate produced under these conditions is not sufficient to support adequate biosynthesis of arginine. This explains why FB335 cannot grow in DLAU, a phenotype called uracil sensitivity ( $\text{Ura}^s$ ). Mutants derived from FB335 that lost pyrimidine regulation of the *pyr* operon were expected to grow in DLAU, a phenotype called uracil resistance ( $\text{Ura}^r$ ). The mutants were selected on DLAU plates incubated in 4%  $\text{CO}_2$ -enriched air since  $\text{CO}_2$  is a substrate for carbamoyl phosphate synthesis and  $\text{CO}_2$  concentrations higher than those found in normal air are required for the growth of some *L. plantarum* CPS mutants (19).

Forty spontaneous mutants were isolated from independent cultures, restreaked on MRS plates, and tested again for the  $\text{Ura}^r$  phenotype on DLAU plates. All conserved their ability to grow in the presence of uracil, suggesting that they harbored stable mutations.

**Phenotypic characterization of 40 independent  $\text{Ura}^r$  mutants.** The physiological abilities of the  $\text{Ura}^r$  mutants were compared to the parental  $\text{Ura}^s$  strain FB335 ( $\Delta\text{carAB}$ ), the prototroph CCM 1904, and the uracil auxotroph PH1021 ( $\Delta\text{pyrD}$ ) (9). Two physiological traits were studied: requirements for uracil and arginine for growth (Table 3) and pyrimidine excretion (Table 1). When the growth requirement for uracil and arginine was assessed with the 40  $\text{Ura}^r$  mutants, three main phenotypes were found (Table 3 and data not shown). Twenty-four mutants were prototrophic for uracil and arginine, as found with the wild-type strain CCM 1904. Fifteen

mutants had a high- $\text{CO}_2$ -requiring phenotype (5), which means that they were only able to grow in the absence of arginine and uracil in  $\text{CO}_2$ -enriched air. One mutant, U7, was auxotrophic for uracil and, unlike the *pyrD* strain, grew in the presence of uracil without  $\text{CO}_2$  enrichment. The prototroph U25 mutant also acquired the ability to grow in the presence of uracil without  $\text{CO}_2$  enrichment.

Compared to the parental strain, some mutants may have lost the ability to control pyrimidine synthesis, which would result in increased levels of pyrimidine synthesis and consequently pyrimidine excretion. Pyrimidine excretion was evaluated in the  $\text{Ura}^r$  mutant collection and compared to that of the parental strain FB335. Excretion of pyrimidines was observed with most mutants (Table 1). The largest amount of pyrimidine nucleotides excreted was 15  $\mu\text{g/ml}$  in strain U25. Phenotypic characterization of the 40 spontaneous  $\text{Ura}^r$  mutants revealed two major types of mutants, the prototrophs and the high- $\text{CO}_2$ -requiring auxotrophs, which can be further subdivided according to their ability to excrete pyrimidines.

**Genetic localization of the mutation conferring  $\text{Ura}^r$  in strain FB335.** Genetic loci potentially implicated in the  $\text{Ura}^r$  phenotype were sequenced and compared to the wild-type genes. Sequencing of the two putative pyrimidine regulators *pyrR1* and *pyrR2* and the *pyr* operon 5' end revealed mutations that may impair pyrimidine-dependent transcription attenuation of the *pyr* operon. Sequencing of the *pyrAa-Ab* genes searched for mutations in the structural genes of the CPS that may affect their activity or their allosteric regulation. Analysis of these loci in the 40 independent mutants allowed us to genetically characterize 26 mutants. All the  $\text{Ura}^r$  strains tested harbored wild-type *pyrR2-pyrAa2-pyrAb2* and *pyrAa1-pyrAb1* genes. The mutations were found in the 5' leader sequence of the *pyr* operon including *pyrR1* (between nucleotides 424 and 1620 in Fig. 2A).

The 26 genetic lesions identified were point mutations in 14 strains; 17- to 454-nucleotide-long deletions in seven strains; and 1- to 26-nucleotide-long insertions in four strains (Table 1). All the mutations were different except for a 17-nucleotide-long deletion in the 5' leader region of the *pyr* operon (strains U1, U8, and U28) and a missense point mutation in *pyrR1* (strains U22 and U29).

**Site-specific mutagenesis of the wild-type strain CCM 1904.** Three mutants were constructed by site-specific mutagenesis of strain CCM 1904 for two reasons. First, the spontaneous  $\text{Ura}^r$  mutants were obtained in a  $\Delta\text{CPS-A}$  derivative of the wild-type strain CCM 1904, and we wanted to see whether the same phenotype was obtained in the wild-type strain. Second, multiple mutational events may have occurred in the spontaneous mutants even though this is unlikely, since the frequency of spontaneous mutations was less than  $10^{-7}$  mutants per plated cell and that most of the mutants studied harbored different mutations. To ensure that strains with the  $\text{Ura}^r$  phenotype can indeed result from a single-locus mutation in the wild-type strain, mutants AE1021, AE1023, and AE1026 were constructed by homologous recombination. One mutation invalidated the repressor PyrR1 (AE1026), and the other two mutations targeted the transcriptional attenuators (AE1021 and AE1023).

In strain AE1026, the D106Y mutation, known to impair *B. subtilis* PyrR binding to the mRNA loop of the *pyr* operon



TABLE 3. Arginine and pyrimidine nutritional needs of the strains studied<sup>a</sup>

Phenotype <sup>b</sup>	Carbon dioxide enrichment	Growth				Mutants
		No addition	Ura	Arg	Ura and Arg	
Prototroph (like wild-type CCM 1904)	No	+	–	+	+	U1, U3, U5, U6, U8, U9, U12, U13, U15-U19, U22-U24, U26, U28, U29, U32, U41, AE1021, AE1026
	Yes	+	+	+	+	
Prototroph	No	+	+	+	+	U25
	Yes	+	+	+	+	
Prototroph Ura <sup>s</sup>	No	+	–	+	+	FB335
	Yes	+	–	+	+	
HCR auxotroph	No	–	–	–	+	U4, U31, U33, U40, AE1023
	Yes	+	+	+	+	
Ura auxotroph	No	–	–	–	+	PH1021
	Yes	–	+	–	+	

<sup>a</sup> Growth was assessed on DLA agar plates supplemented with arginine and uracil and incubated in air or in air enriched with 4% CO<sub>2</sub>. + and –, growth and no growth after 3 days of incubation, respectively.

<sup>b</sup> Ura<sup>s</sup> (sensitive to Ura) refers to the growth inhibition observed when only Ura is provided in the medium. High-CO<sub>2</sub>-requiring (HCR) strains require air-enriched with CO<sub>2</sub> to grow in the absence of both Arg and Ura.

(U4, U23, U26, U33, U1, U8, and U28) harbored mutations in the second transcription attenuator in the intergenic region between the *pyrR1* and *pyrB* genes proposed to be involved in transcription attenuation of the *pyr* operon (Fig. 2A). No aat2 loop was found in the deletion mutants U25 and U1 (U8 and U28 harbored the same deletion as U1) (Fig. 4A). Mutant U25 in addition had a PyrR1 deletion. Point mutations were found at the top of the aat2 loop, either directly within the hexaloop (mutant U4) or at its stem (mutants U23 and U26). These mutations also concomitantly destabilized the at2 loop in mutants U1, U4, U23, and U26 ( $\Delta G$  of about  $-16$  instead of  $-20.9$  kcal mol<sup>-1</sup> calculated in the wild type). These Ura<sup>r</sup> mutants excreted increased pyrimidines (Table 1), suggesting that mutations in the RNA aat2 loop conferred deregulated expression of the *pyr* operon.

Among the seven mutants, only U33 did not excrete significant quantities of pyrimidines (Table 1). The T→G point mutation in U33 slightly altered both the t2 loop ( $\Delta G$  of  $-13.2$  instead of  $-17.6$  kcal mol<sup>-1</sup> as found in the wild type) and the at2 loop ( $\Delta G$  of  $-19.1$  instead of  $-20.9$  kcal mol<sup>-1</sup> in the wild type).

**Different mutations of PyrR1 modulate the levels of deregulation of pyrimidine synthesis.** Eighteen out of 20 *pyrR1* mutants excreted pyrimidine nucleotides in a range between 1 and 15  $\mu$ g/ml (Table 1; 0 and 0.4  $\mu$ g/ml of excreted pyrimidine nucleotides in mutants U33 and U6, respectively). The impact of deletion and insertion events on protein PyrR1 composition is summarized in Fig. 5. In mutants U40 and U17, complete absence of PyrR1 was the result of a lost translation initiation codon. Strain U32 also lost all PyrR1 functional domains with PyrR1 reduced to its 16 first residues. In mutant U31, loss of residues V6 to G57 deleted PyrR1 of two conserved regions (the first mRNA binding region and the PPi loop). Three mutants harbor repressors with less than 25% of the N-terminal part of wild-type PyrR1 due to mutations that introduced translation frameshift (1-nucleotide insert in mutants U19 and

U24; 454-nucleotide deletion in mutant U25). The PyrR1 C-terminal domain has been lost completely in strain U18 (residues D121 to E180) and partially in strain U12 (loss of three residues, H170 to G172).

The 10 different missense mutations found in PyrR1 were located in highly conserved residues, except for residue M120 in mutant U6 (Fig. 6). The strains carrying *pyrR1* point mutations had only partially derepressed phenotypes since excretion was increased to a lesser extent in these mutants ( $\leq 5$   $\mu$ g/ml in AE1026, U3, U5, U6, U9, U13, U15, U16, U22/29, and U41) compared to the deleted PyrR1 strains ( $\geq 5$   $\mu$ g/ml in U12, U17, U18, U19, U24, U25, U31, U32, and U40) (Table 1).

**Optimization of a method for measuring nucleoside triphosphate pools in *L. plantarum*.** The incorporation of radioactively labeled phosphate has previously been used successfully to determine the intracellular nucleotide pool of gram-positive bacteria (14, 21) but has not previously been assessed in *L. plantarum*. Accordingly, the internal nucleoside triphosphate pool of *L. plantarum* was determined by the incorporation of [<sup>33</sup>P]orthophosphate (50  $\mu$ Ci) in exponentially growing cells for two generations. In order to obtain a high specific activity, defined medium DLA was modified by lowering the phosphate concentration. A fivefold reduction of phosphate (from 10 to 2 mM) was shown not to affect growth (data not shown). This medium (DLP) was used for all nucleotide pool determinations. Cells were extracted by transferring aliquots of the culture to formic acid and treating these samples as described in Materials and Methods.

In order to optimize the method, we focused on the concentration of the formic acid used in the extraction. The reported concentrations of formic acid for the extraction of nucleotides from *Salmonella enterica* serovar Typhimurium (1) and *Streptococcus equisimilis* (16) were very different, 0.3 M and 13 M, respectively. We decided to test for the lowest concentration giving quantitative extraction. Final concentrations above 0.95 M formic acid gave quantitative extraction of nucleotides from






FIG. 5. Deletions and insertions found in the spontaneous *Ura<sup>r</sup>* mutants. Rectangles schematize the open reading frame that encodes wild-type PyrR1 protein (white) or chimeric peptides (gray). Insertion and deletion events are delimited by brackets and are oriented outwards and inwards, respectively. The point mutation in mutant U40 is localized with an arrow. The RNA loop binding the PyrR repressor is indicated as anti-terminator (aat2) and is mutated in mutants U25, U1, U8, and U28.

*L. plantarum*. Accordingly, 0.95 M formic acid was used in all of the following experiments.

**Intracellular nucleotide pool quantification.** The nucleotide pool sizes observed in *L. plantarum* are similar to those found in other organisms, whereas its ATP pool is the largest; the others' are two- to sixfold smaller (Table 4). Deletion of the *carAB* operon conferred a slight reduction in pyrimidine pool sizes. This could be explained by a reduced availability of carbamoyl phosphate (Table 4). In the absence of the pyrimidine regulatory protein PyrR1, the *pyr* operon would be over-expressed, resulting in increased amounts of the pyrimidine biosynthetic enzymes. Intuitively, one would expect an increase in pyrimidine nucleotide pool sizes. Surprisingly, this was not observed; strain AE1026 (*pyrR1*) had nucleotide pool sizes similar to that of the wild-type strain (Table 4). On the other hand, in the isolated mutant U25, with the *pyrR1* gene and a part of the attenuation site deleted, the UTP and CTP pool sizes were increased two- to threefold (Table 4). In strain AE1023, the second attenuator in the *pyr* operon was mutated so that the formation of the antiterminator was affected, favoring the formation of the terminator structure (Fig. 4). Consequently, a reduction in the level of the biosynthetic enzymes is expected, resulting in reduced pyrimidine nucleotide pools. The UTP and CTP pool sizes were reduced three- and twofold, respectively, in this mutant (Table 4).

## DISCUSSION

Based on Northern hybridization studies and the characterization of pyrimidine-dependent deregulated mutants, we proposed that *pyr* operon expression is regulated in response to pyrimidine by transcriptional attenuation and that attenuator 2, located in the *pyrR1-pyrB* intergenic region (Fig. 2A and Fig. 4), is functional *in vivo*. The role of attenuator 1, located between the transcriptional start site and *pyrR1* (Fig. 2A), is not clear, since no mutations affecting this structure were obtained. This model will be discussed in view of the different

mutants altered in *pyrR1* and in the *pyr* operon mRNA 5'-end sequence, in particular in attenuator 2.

**Comparison of wild-type PyrR sequences with the altered *L. plantarum* PyrR1 proteins.** Different PyrR1 mutations modulated the levels of deregulation of pyrimidine biosynthesis, as various levels of pyrimidine excretion were observed (Table 1), suggesting that the mutated protein activities were affected *in vivo*. These defects could be due to the change of essential residues implied in mRNA binding, coregulator binding, or dimerization as well as from protein misfolding or reduced mutated *pyrR* expression. The effect of point mutations on PyrR1 function was examined in view of other gram-positive PyrR proteins which have been characterized as functional regulators, such as in *Enterococcus faecalis* (7), *Lactococcus lactis* (13), and *B. subtilis* (23).

The functional domains deduced from the extensive studies in *B. subtilis* PyrR (8, 20, 23) are reported on the PyrR protein sequence alignments in Fig. 6. Since *L. plantarum* PyrR1 has 58% identity with *B. subtilis* PyrR, the effects of PyrR1 mutations were discussed by comparison with the *B. subtilis* PyrR mutational analysis (8, 20). Mutants such as U3, U13, and U16 share relatively high excretion levels (5, 2, and 2  $\mu\text{g/ml}$ , respectively) and harbor mutations in highly conserved residues localized in the dimer loop (Fig. 6). Such residues were mutated in *B. subtilis* mutants: H140A compared to H138R in U13, and R141Q compared to R139C in U16. The *B. subtilis* R141Q mutant was correctly folded, which led the authors to conclude that this region would be required for dimerization or mRNA binding.

Three mutations were found in the  $\alpha 3$  helix. Only its N-terminal part is conserved and was identified in *B. subtilis* PyrR as part of the phosphoribosyltransferase active site involved in coregulator PRPP/UMP binding. As found for the *B. subtilis* PyrR, the D106Y mutation also reduced *L. plantarum* PyrR1 repressor function, since AE1026 was a *Ura<sup>r</sup>* prototroph that excreted pyrimidines. In mutant U41, the R113W mutation is also located in the conserved phosphoribosyltransferase do-




FIG. 6. Sequence alignment of PyrR homologs and localization of *L. plantarum* PyrR1 mutations. Four functional gram-positive bacteria repressors were aligned, *L. plantarum* (accession no. Z54240), *Bacillus subtilis* (accession no. M59757), *Enterococcus faecalis* V583 (accession no. AF044978), and *Lactococcus lactis* subsp. *lactis* (accession no. Q9L4N8), and compared to the gram-negative *Haemophilus influenzae* Rd KW20 (accession no. U32728) homolog. Identical and similar amino acids are highlighted with black and gray backgrounds, respectively. The secondary structure of the *B. subtilis* protein is indicated; arrows and cylinders represent  $\beta$  strands and  $\alpha$  helices, respectively (23). A basic concave surface at the dimer interface was proposed to be required for *B. subtilis* RNA binding and comprised two distinct regions (black lines) (20). The conserved phosphoribosyltransferase (PRTase) structural elements of substrate and product binding involve three regions marked with double lines: the phosphoribosyltransferase domain, the flexible loop which is disordered in the dimer structure, and the PPI loop (23). Dimerization of *B. subtilis* PyrR involves the  $\alpha 3$  helix, the  $\beta 6$  strand, and the dimer loop (20). Amino acid substitutions in *L. plantarum* PyrR1 (\*) and *B. subtilis* (diamonds [8] and triangles [20]) that lead to defects in pyrimidine regulation are marked. Black triangles indicate *B. subtilis* residues that were mutated and impaired mRNA binding without changing protein folding. The names of the *L. plantarum* mutants are indicated above the mutated residues.

main of helix  $\alpha 3$ , but the role of this residue has not previously been studied. In the less conserved region of helix  $\alpha 3$ , the M120I mutation in mutant U6 conferred a  $\text{Ura}^r$  prototroph phenotype with a low excretion level compared to AE1026 and

U41. Thus, mutation M120I would only moderately reduce the repressor function of PyrR1.

Near the phosphoribosyltransferase domain, a disordered flexible loop was observed in the *B. subtilis* PyrR dimeric struc-

TABLE 4. Nucleotide pools in wild-type strain CCM 1904 and isogenic derivatives impaired in pyrimidine metabolism

Strain	Genotype	Generation time (min) <sup>a</sup>	Nucleotide pool size (nmol [mg (dry wt)] <sup>-1</sup> )			
			UTP	CTP	GTP	ATP
CCM 1904	Wild type	103 ± 6	2.7 ± 0.4	0.9 ± 0.2	2.2 ± 0.4	6.2 ± 0.7
FB335	$\Delta carAB$	113 ± 4	2.0 ± 0.2	0.6 ± 0.0	2.0 ± 0.3	5.9 ± 1.4
AE1026	<i>pyrR1</i>	107 ± 5	2.9 ± 0.5	0.9 ± 0.1	2.0 ± 0.4	5.6 ± 0.2
AE1023	at2 mutated	106 ± 11	0.6 ± 0.2	0.4 ± 0.1	3.3 ± 0.4	7.3 ± 1.4
U25	$\Delta carAB pyrR1$	120 ± 10	5.9 ± 1.7	1.3 ± 0.5	1.6 ± 0.6	5.7 ± 0.7
U33	$\Delta carAB at2$	115 ± 5	2.9 ± 0.0	0.9 ± 0.1	2.7 ± 0.3	7.5 ± 0.0

<sup>a</sup> In defined DLP medium in the presence of purines (adenine guanine, hypoxanthine, and xanthine) at final concentrations of 83, 50, 33, and 5  $\mu\text{g/ml}$ , respectively.

ture that would be required for coregulator binding. Mutations in the conserved residues of this flexible loop (U9 and U22 or U29) (Fig. 6) gave mutants that showed higher levels of pyrimidine excretion (2 and 1  $\mu\text{g/ml}$ ; Table 1). The G45R mutation in U5 (Fig. 6) is expected to affect the PPI loop. This mutation could therefore lead to impaired coregulator binding in PyrR1. Finally, a point mutation, D168N (mutant U15), and a short deletion of three residues (170 to 172 in mutant U12) were localized in the C-terminal part. No similar *B. subtilis* mutations were obtained in this region, and no particular function has been proposed for this region. Mutations in conserved regions of *L. plantarum* PyrR1 and *B. subtilis* PyrR (flexible loop; phosphoribosyltransferase domain; dimer loop/mRNA binding, Fig. 6) led to deregulation, suggesting that these proteins are functionally similar.

***pyr* operon mRNA 5'-end sequence is recruited for *pyr* transcription attenuation.** Pyrimidine-controlled transcription attenuation was lost in mutants harboring mutations in attenuator 2 localized between *pyrR1* and *pyrB* (summarized in Fig. 4). These mutations either increased or decreased *pyr* operon transcription. The first set of mutations led to pyrimidine-independent increased transcription by destabilization of the anti-antiterminator *aat2* RNA loop so that termination was inefficient. The second set of mutations led to pyrimidine-independent decreased transcription by destabilizing the anti-terminator *at2* RNA loop so that terminator *t2* formation was favored. This will be discussed below.

Increased transcription readthrough after the *pyrR1* gene was correlated to mutations in the RNA *aat2* loop. Strains with mutations in attenuator 2 had increased pyrimidine nucleotide excretion (AE1021, U1, and U4 in Table 1). In mutant U1, a 13-nucleotide-long deletion (circled nucleotides in Fig. 4A) resulted in the loss of the proposed *aat2* RNA loop. Within this *aat2* RNA loop, the terminal hexaloop (underlined in Fig. 4A) needed to be conserved to observe regulation with point mutations in the hexaloop itself (mutant AE1021, CAaAGA, and mutant U4, CAGAuA; mutation indicated in lowercase) or at its stem (mutants U23 and U26; Fig. 4A). Thus, the *aat2* loop and in particular the hexaloop seem to be required to terminate transcription after *pyrR1* and inhibit de novo pyrimidine nucleotide synthesis in vivo.

Previous in vitro experiments suggested that *B. subtilis* PyrR tightly binds to a 28-nucleotide-long minimal RNA that contains the hexaloop and its stem (2). Based on alignments of known RNA PyrR-binding sites, a consensus PyrR-binding loop was proposed with the terminal sequence CNGNGA (2). Within this hexaloop consensus, the two G's were replaced individually in mutants AE1021 and U4 and led to loss of repression. These data, combined with secondary-structure similarities with other PyrR-binding loops (data not shown), strongly suggest that in *L. plantarum* as in *B. subtilis*, the anti-antiterminator loop, and in particular the terminal hexaloop, is involved in PyrR binding and transcription attenuation of the *pyr* operon.

Increased transcription termination after *pyrR1* was found in the high-CO<sub>2</sub>-requiring mutant AE1023 that harbors an unstable *at2* RNA loop. As expected from such a mutant that would have reduced transcription of the *pyr* operon, no pyrimidine nucleotide excretion was observed (Table 1). Finally, the measured intracellular UTP and CTP pools were reduced in mu-

tant AE1023 compared to the wild type (Table 4). We conclude that impairment of the *at2* loop leads to the loss of pyrimidine-controlled transcription termination of the *pyr* operon. Despite the fact that AE1023 and mutant U33 are high-CO<sub>2</sub>-requiring auxotrophs (Table 3), mutant U33 has slightly increased intracellular UTP and CTP pools (Table 4, compare strains FB335 and U33). Strain U33 has a U→G mutation in the second attenuation site. This mutation is predicted to partially destabilize terminator *t2* as well as antiterminator *at2* (Fig. 4A and B). The position of this mutation 27-nucleotides downstream of the *aat2* loop may also be a transcriptional pausing site (25). Thus, how pyrimidine regulation is lost in Ura<sup>r</sup> mutant U33 remains unclear.

**Carbamoyl phosphate pools determine the ability of *L. plantarum* to grow in normal air without CO<sub>2</sub> enrichment.** Carbamoyl phosphate is required for arginine and pyrimidine biosynthesis. The pyrimidine-regulated CPS-P can produce carbamoyl phosphate for either arginine or pyrimidine biosynthesis, but the resulting pyrimidine nucleotide pools are lower in a strain that harbors only CPS-P (Table 4, compare the  $\Delta\text{carAB}$  mutant strain to the wild-type strain). Therefore, in the genetic context of FB335, the reduced carbamoyl phosphate pool limits UMP synthesis. From the differences in the concentrations of UTP and CTP in the wild-type and FB335, we deduced that CPS-A activity provides about one third of the carbamoyl phosphate required for arginine and pyrimidine synthesis in the conditions tested (liquid DLP medium without agitation). The lower UMP and CTP pools had no effect on FB335 growth in DLA medium since FB335 was prototrophic for the pyrimidines and arginine and strain FB335 and the wild-type strain had similar generation times (Table 4). On the other hand, when the pyrimidine nucleotide pools dropped by more than a factor of 2, such as in strain AE1023 (Table 4), the growth of *L. plantarum* on DLA became dependent on higher levels of supplied CO<sub>2</sub>, as AE1023 has the high-CO<sub>2</sub>-requiring phenotype (Table 4). Thus, CO<sub>2</sub> may be the limiting reactant in carbamoyl phosphate synthesis in normal air.

This hypothesis is in agreement with the following genetic data. In the FB335 genetic context, the need for CO<sub>2</sub> was increased in cells that needed to produce more carbamoyl phosphate due to inefficient recycling of preformed uracil derived from RNA degradation. This was found in 11 of the 40 Ura<sup>r</sup> mutants selected in this work, which harbored mutations in the *upp* gene, encoding uracil phosphoribosyltransferase (EC 2.4.2.9). These *upp* mutants had the high-CO<sub>2</sub>-requiring phenotype and grew only in CO<sub>2</sub>-enriched conditions (unpublished data). Increased CPS-P concentrations resulting from constitutive high *pyr* operon transcription conferred the ability to grow in air (mutants with impaired *pyrR1* or altered RNA *aat2* loops). We therefore conclude that *L. plantarum* growth is prevented when the intracellular carbamoyl phosphate pool is low. Reduced carbamoyl phosphate pools may result from inadequate CPS activity because of depletion in bicarbonate or from low CPS expression, as observed in strain AE1023.

**Is PyrR1 only partially controlling *pyr* operon expression?** Higher amounts of pyrimidine excretion up to 15  $\mu\text{g/ml}$  were observed when, in addition to *pyrR1* deletion, the anti-antiterminator loop *aat2* was deleted in mutant U25. The mutants U17 and U40, missing only the *pyrR1* gene, excreted 7 to 8  $\mu\text{g}$  of pyrimidine nucleotides per ml. This suggested that *pyrR1*



deletion alone does not lead to a total derepression phenotype and that the *aat2* loop would be formed even in the absence of PyrR1 binding. On the contrary, deletion of *pyrR* from the *B. subtilis* chromosome resulted in constitutive, elevated expression of aspartate transcarbamylase, which is encoded by the third gene of the *pyr* operon (24).

Unlike that of *B. subtilis*, the *L. plantarum* genome harbors a second putative repressor gene named *pyrR2* (10). In this study, no spontaneous mutations were found in *pyrR2*. This may suggest that the screening procedure prevented *pyrR2* mutant selection or that the role of *pyrR2* in pyrimidine regulation may be minor compared to that of *pyrR1*. Site-directed mutagenesis of the *pyrR* loci is required to test their involvement in *pyr* operon regulation. This issue is currently being investigated.

#### ACKNOWLEDGMENTS

We gratefully acknowledge Céline Sutter for technical assistance and Jean-Claude Hubert for valuable discussions on pyrimidine metabolism in *Lactobacillus plantarum*.

F.B. received a grant from the EU (Major Research Infrastructure grant) for her stay at the Danish Center for Advanced Food Studies.

#### REFERENCES

1. Beck, C. F., J. Neuhaud, E. Thomassen, J. L. Ingraham, and E. Kleker. 1974. *Salmonella typhimurium* mutants defective in cytidine monophosphate kinase (*cmk*). J. Bacteriol. **120**:1370–1379.
2. Bonner, E. R., J. N. D'Elia, B. K. Billips, and R. L. Switzer. 2001. Molecular recognition of *pyr* mRNA by the *Bacillus subtilis* attenuation regulatory protein PyrR. Nucleic Acids Res. **29**:4851–4865.
3. Bouia, A., F. Bringel, L. Frey, A. Belarbi, A. Guyonvarch, B. Kammerer, and J. C. Hubert. 1990. Cloning and structure of the *pyrE* gene of *Lactobacillus plantarum* CCM 1904. FEMS Microbiol. Lett. **57**:233–238.
4. Bringel, F., L. Frey, S. Boivin, and J. C. Hubert. 1997. Arginine biosynthesis and regulation in *Lactobacillus plantarum*: the *carA* gene and the *argCJBDF* cluster are divergently transcribed. J. Bacteriol. **179**:2697–2706.
5. Bringel, F., and J. C. Hubert. 2003. Extent of genetic lesions of the arginine and pyrimidine biosynthetic pathways in *Lactobacillus plantarum*, *L. paraplantarum*, *L. pentosus*, and *L. casei*: prevalence of CO<sub>2</sub> dependent auxotrophs and characterization of deficient *arg* genes in *L. plantarum*. Appl. Environ. Microbiol. **69**:2674–2683.
6. Elagöz, A., A. Abdi, J. C. Hubert, and B. Kammerer. 1996. Structure and organisation of the pyrimidine biosynthesis pathway genes in *Lactobacillus plantarum*: a PCR strategy for sequencing without cloning. Gene **182**:37–43.
7. Ghim, S. Y., C. C. Kim, E. R. Bonner, J. N. D'Elia, G. K. Grabner, and R. L. Switzer. 1999. The *Enterococcus faecalis pyr* operon is regulated by autogenous transcriptional attenuation at a single site in the 5' leader. J. Bacteriol. **181**:1324–1329.
8. Ghim, S. Y., and R. L. Switzer. 1996. Mutations in *Bacillus subtilis* PyrR, the *pyr* regulatory protein, with defects in regulation by pyrimidines. FEMS Microbiol. Lett. **137**:13–18.
9. Horvath, P. 2000. Dynamique, évolution et expression de génomes de bactéries lactiques: cas du métabolisme des pyrimidines chez *Lactobacillus plantarum* CCM 1904. Thèse de doctorat. Université Louis-Pasteur, Strasbourg, France.
10. Kleerebezem, M., J. Boekhorst, R. van Kranenburg, D. Molenaar, O. P. Kuipers, R. Leer, R. Turchini, S. A. Peters, H. M. Sandbrink, M. W. Fiers, W. Stiekema, R. M. Lankhorst, P. A. Bron, S. M. Hoffer, M. N. Groot, R. Kerkhoven, M. de Vries, B. Ursing, W. M. de Vos, and R. J. Siezen. 2003. Complete genome sequence of *Lactobacillus plantarum* WCFS1. Proc. Natl. Acad. Sci. USA **100**:1990–1995.
11. Lu, Y., R. J. Turner, and R. L. Switzer. 1995. Roles of the three transcriptional attenuators of the *Bacillus subtilis* pyrimidine biosynthetic operon in the regulation of its expression. J. Bacteriol. **177**:1315–1325.
12. Martinussen, J., P. Glaser, P. S. Andersen, and H. H. Saxild. 1995. Two genes encoding uracil phosphoribosyltransferase are present in *Bacillus subtilis*. J. Bacteriol. **177**:271–274.
13. Martinussen, J., J. Schallert, B. Andersen, and K. Hammer. 2001. The pyrimidine operon *pyrRBP-carA* from *Lactococcus lactis*. J. Bacteriol. **183**:2785–2794.
14. Martinussen, J., S. L. Wadskov-Hansen, and K. Hammer. 2003. Two nucleoside uptake systems in *Lactococcus lactis*: competition between purine nucleosides and cytidine allows for modulation of intracellular nucleotide pools. J. Bacteriol. **185**:1503–1508.
15. Masson, A., B. Kammerer, and J. C. Hubert. 1994. Selection and biochemical studies of pyrimidine-requiring mutants of *Lactobacillus plantarum*. J. Appl. Bacteriol. **77**:88–95.
16. Mechold, U., and H. Malke. 1997. Characterization of the stringent and relaxed responses of *Streptococcus equisimilis*. J. Bacteriol. **179**:2658–2667.
17. Neuhaud, J., and R. A. Kelln. 1996. Biosynthesis and conversion of pyrimidines, p. 580–599. In F. C. Neidhardt, R. Curtiss, J. L. Ingraham, E. C. C. Linn, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), *Escherichia coli* and *Salmonella*: cellular and molecular biology. ASM Press, Washington, D.C.
18. Nicoloff, H., and F. Bringel. 2003. IS*Lpl1* is a functional IS30-related insertion element in *Lactobacillus plantarum* that is also found in other lactic acid bacteria. Appl. Environ. Microbiol. **69**:5832–5840.
19. Nicoloff, H., J. C. Hubert, and F. Bringel. 2000. In *Lactobacillus plantarum*, carbamoyl phosphate is synthesized by two carbamoyl-phosphate synthetases (CPS): carbon dioxide differentiates the arginine-repressed from the pyrimidine-regulated CPS. J. Bacteriol. **182**:3416–3422.
20. Savacool, H. K., and R. L. Switzer. 2002. Characterization of the interaction of *Bacillus subtilis* PyrR with *pyr* mRNA by site-directed mutagenesis of the protein. J. Bacteriol. **184**:2521–2528.
21. Saxild, H. H., and P. Nygaard. 1991. Regulation of levels of purine biosynthetic enzymes in *Bacillus subtilis*: effects of changing purine nucleotide pools. J. Gen. Microbiol. **137**:2387–2394.
22. Switzer, R. L., R. J. Turner, and Y. Lu. 1999. Regulation of the *Bacillus subtilis* pyrimidine biosynthetic operon by transcriptional attenuation: control of gene expression by an mRNA-binding protein. Prog. Nucleic Acids Res. Mol. Biol. **62**:329–367.
23. Tomchick, D. R., R. J. Turner, R. L. Switzer, and J. L. Smith. 1998. Adaptation of an enzyme to regulatory function: structure of *Bacillus subtilis* PyrR, a *pyr* RNA-binding attenuation protein and uracil phosphoribosyltransferase. Structure **6**:337–350.
24. Turner, R. J., Y. Lu, and R. L. Switzer. 1994. Regulation of the *Bacillus subtilis* pyrimidine biosynthetic (*pyr*) gene cluster by an autogenous transcriptional attenuation mechanism. J. Bacteriol. **176**:3708–3722.
25. Zhang, H., and R. L. Switzer. 2003. Transcriptional pausing in the *Bacillus subtilis pyr* operon in vitro: a role in transcriptional attenuation? J. Bacteriol. **185**:4764–4771.